Asymptomatic neurocognitive disorders in patients infected by HIV: Fact or fiction?

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Torti, Carlo ^a   Focà, Emanuele ^a   Cesana, Bruno M ^a   Lescure, Francois X ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Asymptomatic neurocognitive impairment; Haart; Hiv; Hiv dementia

Indexed keywords

BIOLOGICAL MARKER;

ASYMPTOMATIC DISEASE; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; FOLLOW UP; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NEUROIMAGING; NONHUMAN; NOTE; POPULATION RISK; ARTICLE; COGNITIVE DEFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ASYMPTOMATIC DISEASES; COGNITION DISORDERS; HIV INFECTIONS; HUMANS;

EID: 84856599412     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-138     Document Type: Note

References (35)

1. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155. 10.1146/annurev-med-042909-093756, 21090961.
2. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 2011, 53:836-842. 10.1093/cid/cir524, 21921226.
3. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, . CHARTER Group HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010, 75:2087-2096. 10.1212/WNL.0b013e318200d727, 2995535, 21135382, CHARTER Group.
4. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, Kronborg G, Larsen CS, Obel N. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011, 52:235-243. 10.1093/cid/ciq041, 21288850.
5. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250.
6. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010, 50:773-778. 10.1086/650538, 20100092.
7. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:168-173. 10.1097/QAI.0b013e31815ace97, 2628632, 17971711.
8. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009, 73:1982-1987. 10.1212/WNL.0b013e3181c5b445, 2790234, 19907013.
9. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
10. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002, 59:1563-1567.
11. Cherner M, Cysique L, Heaton RK, Marcotte TD, Ellis RJ, Masliah E, Grant I, . HNRC Group Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol 2007, 13:23-28. 10.1080/13550280601089175, 17454445, HNRC Group.
12. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Ottobre 2011, Last accessed on December 14, 2011., http://www.salute.gov.it/imgs/C_17_pubblicazioni_1301_allegato.pdf
13. Gisslèn M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Inf Dis 2011, 11:356.
14. Vita A, De Peri L, Barlati S, Cacciani P, Deste G, Poli R, Agrimi E, Cesana BM, Sacchetti E. Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting. Schizophr Res 2011, 133:223-231. 10.1016/j.schres.2011.08.010, 21907544.
15. Castellon SA, Hinkin CH, Myers HF. Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection. J Int Neuropsychol Soc 2000, 6:336-347. 10.1017/S1355617700633088, 10824505.
16. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Ach Gen Psychiatry 2001, 58:721-728.
17. Zhang L, Looney D, Taub D, Chang SL, Way D, Witte MH, Graves MC, Fiala M. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998, 4:619-626. 10.3109/13550289809114228, 10065903.
18. Meyerhoff DJ. Effects of alcohol and HIV infection on the central nervous system. Alcohol Res Health 2001, 25:288-298.
19. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW, Robertson KR. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006, 20:1591-1595. 10.1097/01.aids.0000238404.16121.47, 16868439.
20. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW, . INSIGHT SMART Study Group Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75:864-873. 10.1212/WNL.0b013e3181f11bd8, 2938971, 20702792, INSIGHT SMART Study Group.
21. Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, Buxton RB, Benson D, Smith DM, Little SJ, Richman DD, Moore DJ, Ellis RJ, . HNRC group Resting cerebral blood flow: a potential biomarker of the effect of HIV in the brain. Neurology 2009, 73:702-708. 10.1212/WNL.0b013e3181b59a97, 2734291, 19720977, HNRC group.
22. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011, 76:1403-1409. 10.1212/WNL.0b013e31821670fb, 21502598.
23. Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter CC. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS 2001, 15:341-345. 10.1097/00002030-200102160-00007, 11273214.
24. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21:1915-1921. 10.1097/QAD.0b013e32828e4e27, 17721099.
25. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001, 56:37-42.
26. Paul RH, Sacktor NC, Valcour V, Tashima KT. HIV and the Brain. New Challenges in the Modern Era 2009, Humana Press, 1.
27. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B, . HIV Neuroimaging Consortium Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011, 25:625-633. 10.1097/QAD.0b013e3283427da7, 21297425, HIV Neuroimaging Consortium.
28. Letendre S, Croteau D, Ellis R, Clifford D, Gelman B, Marra C, McArthur J, McCutchan A, Simpson D, Grant I, . CHARTER Group Lower CSAR Are Associated with Global Neurocognitive Impairment in Antiretroviral-treated People with HIV. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA 2011, Abstract 408. CHARTER Group.
29. Anderson C, Sacktor N, McArthur J, Nath A. CSF Neurofilament H Levels in HIV+ Individuals with Normal Cognition Predict Deterioration. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA 2011, Abstract 407.
30. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011, 25:561-575. 10.1097/QAD.0b013e3283437f9a, 21160410.
31. Carsenti-Dellamonica H, Vassallo M, Pradier C, Durant J, Harvey-Langton A, Lebrun-Frenay C, Cottalorda J, Biscay V, Ticchioni M, Dellamonica P, . Neuradapt Study Group LPS may be a predictive factor even in mild forms of HIV-associated neurocognitive impairment: sub-analysis of the neuradapt study. 18th Conference on Retroviruses and Opportunistic Infections, Boston MA 2011, Abstract 404. Neuradapt Study Group.
32. Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, Soulas C, González RG, Ratai EM, Williams KC. Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. PLoS One 2011, 6:e18688. 10.1371/journal.pone.0018688, 3071838, 21494695.
33. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell Immunol 2011, 267:109-123. 10.1016/j.cellimm.2010.12.004, 21292246.
34. Chong WK, Paley M, Wilkinson ID, Hall-Craggs MA, Sweeney B, Harrison MJ, Miller RF, Kendall BE. Localized cerebral proton MR spectroscopy in HIV infection and AIDS. AJNR Am J Neuroradiol 1994, 15:21-25.
35. Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller EN. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999, 53:782-789.